Drugs by condition
Drugs approved for sickle cell disease
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
8
Still marketed, NDA or BLA
Drug classes
4
Novel drugs
3
New molecular entities and new biologics
In development
10
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for sickle cell disease.
- Xromi (Hydroxyurea) · Nova Labs LTD Priority reviewOrphanApr 4, 2024
- Ferriprox (Deferiprone) · Chiesi Accelerated approvalOrphanMay 19, 2020
- Adakveo (Crizanlizumab-Tmca) · Novartis Pharms Corp NovelBreakthrough therapyPriority reviewOrphanNov 15, 2019
- Siklos (Hydroxyurea) · Theravia OrphanDec 21, 2017
- Endari (L-Glutamine) · Emmaus Medcl OrphanJul 7, 2017
All approved drugs for sickle cell disease, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 4 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Drugs in development for sickle cell disease
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- FT-4202EtavopivatPhase 36 trials
Forma Therapeutics, Inc. · Sickle Cell Disease, Thalassemia
- Exa-celPhase 31 trial
Vertex Pharmaceuticals · Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- HBI-002Phase 22 trials
Hillhurst Biopharmaceuticals, Inc. · Parkinson Disease, Anemia, Sickle Cell
- TebapivatAG-946Phase 22 trials
Agios Pharmaceuticals, Inc. · Myelodysplastic Syndromes, Sickle Cell Disease
- AnumigilimabPhase 21 trial
CSL Behring · Sickle Cell Disease
- BEAM-101Phase 21 trial
Beam Therapeutics Inc. · Sickle Cell Disease
- BMS-986470Phase 21 trial
Bristol Myers Squibb · Anemia, Sickle Cell, Healthy Volunteers
- CSL889Phase 21 trial
CSL Behring · Sickle Cell Disease Vaso-occlusive Crisis
- ITU512Phase 21 trial
Novartis · Sickle Cell Disease
More on sickle cell disease: recruiting trials · published research
Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Hemophilia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.